Press Release Large Canadian Heart Valve Study Provides Evidence of On-X® Heart Valve Superior Performance AUSTIN, TX (December 13, 2010) – Austin-based On-X® Life Technologies, Inc. (On-X LTI), today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X Prosthetic Heart Valve in the November issue of The Journal of [...]
On-X LTI Enters License and Development Agreement
December 10, 2009 By
Press Release On-X Life Technologies Enters License and Development Agreement with Cleveland Clinic for Surgical System to Repair Mitral Valve Chordae System is intended to improve mitral valve repair and simplify procedure for cardiac surgeons AUSTIN, TX (December 8, 2009) – Austin-based On-X® Life Technologies, Inc. (On-X LTI), manufacturers of the On-X® Prosthetic Heart Valve [...]
On-X LTI Completes Enrollment
October 20, 2009 By
Press Release On-X Life Technologies Completes Enrollment in High-Risk Patient Group of Low Anticoagulation Trial Data from the PROACT Trial may provide evidence that the On-X valve may be appropriately maintained at lower levels of anticoagulation AUSTIN, TX (October 20, 2009) – Austin-based On-X® Life Technologies, Inc. (On-X LTI), manufacturers of the On-X® Prosthetic Heart [...]
On-X LTI Doubles Manufacturing Space
March 9, 2009 By
Press Release On-X Life Technologies Doubles Manufacturing Space in Austin Increasing demand for On-X Prosthetic Heart Valve and orthopedic implant products make capacity expansion necessary AUSTIN, TX (March 20, 2009) – Austin-based On-X Life Technologies, Inc. (On-X LTI), manufacturers of the On-X Prosthetic Heart Valve and On-X carbon products for orthopedic implants, announced today that [...]
On-X Valve Reduced Anticoagulation Clinical Trial
January 10, 2006 By
Press Release On-X Valve Reduced Anticoagulation Clinical Trial AUSTIN, TX (January 13, 2006) – The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) clinical trial of the On-X Prosthetic Heart Valve at reduced anticoagulation levels following review and approval by clinical centers. Successful completion of the clinical study could result [...]
Strategic Alliance with QAS
August 23, 2005 By
Press Release MCRI Forms Strategic Alliance with QAS for Self-Monitoring of Anticoagulation by On-X Heart Valve Patients Partnership will provide tools to On -X valve recipients to improve anticoagulation levels and encourage better self-monitoring. AUSTIN, TX (August 23, 2005) – Medical Carbon Research Institute L.L.C. (MCRI), manufacturer of the On-X prosthetic heart valve, today announced [...]
Low Postoperative Complications with On-X Valve
June 25, 2003 By
Press Release Clinical Study Reinforces Low Postoperative Complications with On-X Valve AUSTIN, TX (June 25, 2003) – Medical Carbon Research Institute, L.L.C. (“MCRI”), manufacturer of the On-X(R) Prosthetic Heart Valve, announced the presentation of clinical study results comparing rates of late complications (thrombosis, major bleeding and major thromboembolism) for the On-X valve and competing valves [...]
US FDA Mitral Valve Approval
March 6, 2003 By
Newsroom U.S. FDA Mitral Valve Approval AUSTIN, TX (March 06, 2002) – The U.S. FDA issues premarket approval for the On-X mitral valve. All On-X valves are now available in the United States.
Australian TGA Approves On-X Valves
March 25, 2002 By
Newsroom Australian TGA Approves On-X Valves AUSTIN, TX (March 14, 2002) – The Australian Therapeutic Goods Administration announce the inclusion of On-X valves in the Australian Register of Therapeutic Goods. On-X valves are now available in Australia and New Zealand.
Medical Design Excellence Award
March 1, 2002 By
Newsroom MCRI Named Winner of Medical Design Excellence Award AUSTIN, TX (March 01, 2002) – CANON COMMUNICATIONS LLC announced MCRI a winner of the fifth annual Medical Design Excellence Awards (MDEA) competition in the “Implant and Tissue-Replacement Products” category.
